MyFinsight
Home
Blog
About
ANAPTYSBIO, INC (ANAB)
ANAPTYSBIO, INC (ANAB)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$10,273K
Free Cash flow
-$25,936K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Sales and maturities of investme...
Non-cash interest expense for sa...
Stock-based compensation
Others
Negative Cash Flow Breakdown
Net loss
Accounts payable and other liabi...
Principal repayment of liability...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net loss
-52,884
49,614
15,113
-77,959
Depreciation and amortization
130
131
140
288
Stock-based compensation
14,218
8,506
9,157
18,409
Non-cash interest expense
-
-
-22,515
-37,667
Accretion/amortization of investments, net
8
340
1,130
3,264
Amortization of right-of-use assets operating
480
475
470
919
Non-cash interest expense for sale of future royalties
20,859
79,893
-
-
Receivables from collaborative partners
-8,103
-41,835
54,267
-19,347
Prepaid expenses and other assets
-1,501
-971
303
-944
Accounts payable and other liabilities
-17,819
-22,412
-18,561
-46,354
Deferred income
0
-
-
-
Operating lease liabilities
-499
-494
-490
-941
Net cash used in operating activities
-25,919
97,997
-27,356
-50,944
Purchase of investments
0
0
19,656
176,755
Sales and maturities of investments
35,000
73,501
122,950
228,079
Purchases of property and equipment
17
1
12
74
Net cash provided by investing activities
34,983
73,500
103,282
51,250
Payments for offering costs, net
-
0
0
-
Proceeds from public offerings, net of underwriters' fees
-
0
0
-
Payments for debt issuance costs
-
-
0
0
Proceeds from issuance of common stock
14,021
12,212
336
1,713
Repurchase and retirements of common stock
0
3,384
9,720
55,522
Proceeds from the sale of future royalties
-
0
0
0
Payment for net share settlement of equity awards
0
0
0
1,451
Payments for issuance costs related to the sale of future royalties
-
0
-
-
Principal repayment of liability for sale of future royalties
12,812
51,962
1,007
23,828
Net cash provided by (used in) financing activities
1,209
-43,134
-10,391
-79,088
Net increase (decrease) in cash and cash equivalents
10,273
128,363
65,535
-78,782
Cash and cash equivalents, beginning of period
238,196
109,833
123,080
-
Cash and cash equivalents, end of period
248,469
238,196
109,833
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Sales and maturities
of investments
$35,000K
Proceeds from issuance of
common stock
$14,021K
Net cash provided by
investing activities
$34,983K
Net cash provided by
(used in) financing...
$1,209K
Canceled cashflow
$17K
Canceled cashflow
$12,812K
Net increase
(decrease) in cash and cash...
$10,273K
Canceled cashflow
$25,919K
Purchases of property and
equipment
$17K
Non-cash interest
expense for sale of...
$20,859K
Stock-based compensation
$14,218K
Receivables from
collaborative partners
-$8,103K
Prepaid expenses and
other assets
-$1,501K
Amortization of right-of-use
assets operating
$480K
Depreciation and
amortization
$130K
Principal repayment of
liability for sale of...
$12,812K
Net cash used in
operating activities
-$25,919K
Canceled cashflow
$45,291K
Net loss
-$52,884K
Accounts payable and
other liabilities
-$17,819K
Operating lease
liabilities
-$499K
Accretion/amortization of investments,
net
$8K
Buy us a coffee